Disclosures for "ART5803, a First-in-class Precision Medicine to Treat Anti-NMDA Receptor Encephalitis, First-in-human Phase 1 Clinical Safety and Pharmacokinetic Profile"
-
Dr. Gokhale has received personal compensation for serving as an employee of Arialys Therapeutics. Dr. Gokhale has stock in Arialys.
-
Ms. Maurer has received personal compensation for serving as an employee of Arialys Therapeuticss, Inc.. Ms. Maurer has received personal compensation for serving as an employee of ESCAPE Bio. Ms. Maurer has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for ReCode Therapeutics. Ms. Maurer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Momentum Pharma. Ms. Maurer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ESCAPE Bio. Ms. Maurer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys Therapeutics.
-
Ms. Purcell has received personal compensation for serving as an employee of Arialys Therapeutics.
-
Dr. Singh has nothing to disclose.
-
Dr. Billic has nothing to disclose.
-
Dr. Jefson has received personal compensation for serving as an employee of Arialys Therapeutics. Dr. Jefson has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Arialys Therapeutics.
-
Dr. Flynn has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Artiva. Dr. Flynn has received personal compensation in the range of $500,000-$999,999 for serving as an officer or member of the Board of Directors for Arialys.
-
Dr. Matsumoto has received personal compensation for serving as an employee of Arialys Therapeutics, Inc.. Dr. Matsumoto has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Arialys Therapeutics, Inc.. Dr. Matsumoto has stock in Arialys Therapeutics, Inc.. Dr. Matsumoto has received intellectual property interests from a discovery or technology relating to health care.